S&P 500   4,565.93 (-0.04%)
DOW   36,019.39 (+0.19%)
QQQ   386.83 (-0.51%)
AAPL   190.14 (+0.10%)
MSFT   372.52 (-1.69%)
META   321.92 (-1.60%)
GOOGL   130.99 (-1.16%)
AMZN   146.15 (+0.04%)
TSLA   233.36 (-2.80%)
NVDA   464.76 (-0.63%)
NIO   7.07 (-2.75%)
BABA   72.95 (-2.58%)
AMD   119.32 (-1.52%)
T   16.68 (+0.66%)
F   10.43 (+1.66%)
MU   75.63 (-0.64%)
CGC   0.56 (+0.86%)
GE   122.65 (+0.70%)
DIS   92.07 (-0.67%)
AMC   6.93 (+4.21%)
PFE   28.93 (-5.05%)
PYPL   58.28 (+1.16%)
XOM   103.98 (+1.21%)
S&P 500   4,565.93 (-0.04%)
DOW   36,019.39 (+0.19%)
QQQ   386.83 (-0.51%)
AAPL   190.14 (+0.10%)
MSFT   372.52 (-1.69%)
META   321.92 (-1.60%)
GOOGL   130.99 (-1.16%)
AMZN   146.15 (+0.04%)
TSLA   233.36 (-2.80%)
NVDA   464.76 (-0.63%)
NIO   7.07 (-2.75%)
BABA   72.95 (-2.58%)
AMD   119.32 (-1.52%)
T   16.68 (+0.66%)
F   10.43 (+1.66%)
MU   75.63 (-0.64%)
CGC   0.56 (+0.86%)
GE   122.65 (+0.70%)
DIS   92.07 (-0.67%)
AMC   6.93 (+4.21%)
PFE   28.93 (-5.05%)
PYPL   58.28 (+1.16%)
XOM   103.98 (+1.21%)
S&P 500   4,565.93 (-0.04%)
DOW   36,019.39 (+0.19%)
QQQ   386.83 (-0.51%)
AAPL   190.14 (+0.10%)
MSFT   372.52 (-1.69%)
META   321.92 (-1.60%)
GOOGL   130.99 (-1.16%)
AMZN   146.15 (+0.04%)
TSLA   233.36 (-2.80%)
NVDA   464.76 (-0.63%)
NIO   7.07 (-2.75%)
BABA   72.95 (-2.58%)
AMD   119.32 (-1.52%)
T   16.68 (+0.66%)
F   10.43 (+1.66%)
MU   75.63 (-0.64%)
CGC   0.56 (+0.86%)
GE   122.65 (+0.70%)
DIS   92.07 (-0.67%)
AMC   6.93 (+4.21%)
PFE   28.93 (-5.05%)
PYPL   58.28 (+1.16%)
XOM   103.98 (+1.21%)
S&P 500   4,565.93 (-0.04%)
DOW   36,019.39 (+0.19%)
QQQ   386.83 (-0.51%)
AAPL   190.14 (+0.10%)
MSFT   372.52 (-1.69%)
META   321.92 (-1.60%)
GOOGL   130.99 (-1.16%)
AMZN   146.15 (+0.04%)
TSLA   233.36 (-2.80%)
NVDA   464.76 (-0.63%)
NIO   7.07 (-2.75%)
BABA   72.95 (-2.58%)
AMD   119.32 (-1.52%)
T   16.68 (+0.66%)
F   10.43 (+1.66%)
MU   75.63 (-0.64%)
CGC   0.56 (+0.86%)
GE   122.65 (+0.70%)
DIS   92.07 (-0.67%)
AMC   6.93 (+4.21%)
PFE   28.93 (-5.05%)
PYPL   58.28 (+1.16%)
XOM   103.98 (+1.21%)

MaxCyte Stock Price, News & Analysis (NASDAQ:MXCT)

$4.80
+0.05 (+1.05%)
(As of 10:33 AM ET)
Compare
Today's Range
$4.64
$4.80
50-Day Range
$2.60
$4.87
52-Week Range
$2.45
$6.11
Volume
108,986 shs
Average Volume
591,131 shs
Market Capitalization
$497.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

MaxCyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Upside
$9.50 Price Target
Short Interest
Healthy
3.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of MaxCyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$60,050 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

273rd out of 948 stocks

Commercial Physical Research Industry

7th out of 13 stocks


MXCT stock logo

About MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

Craig Hallum Initiates Coverage on MaxCyte (NASDAQ:MXCT)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
MaxCyte Inc MXCT
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why Is MaxCyte (MXCT) Stock Down 21% Today?
PRTS, CRBU and NDLS are among after hour movers
Recap: MaxCyte Q1 Earnings
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MXCT
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$12.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+100.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-23,570,000.00
Pretax Margin
-98.44%

Debt

Sales & Book Value

Annual Sales
$38.05 million
Book Value
$2.25 per share

Miscellaneous

Free Float
97,361,000
Market Cap
$491.99 million
Optionable
Optionable
Beta
0.84
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Douglas Arthur Doerfler (Age 67)
    Founder, President, CEO & Executive Director
    Comp: $1.2M
  • Dr. Cenk Sumen Ph.D. (Age 49)
    Chief Scientific Officer
    Comp: $575.6k
  • Mr. Maher Masoud (Age 48)
    Executive VP, General Counsel & Secretary
    Comp: $612.07k
  • Mr. Douglas J. Swirsky CFA (Age 54)
    CPA, Chief Financial Officer
  • Mr. Ronald Evan Holtz CPA (Age 65)
    Ph.D., Executive Vice President of Administration
    Comp: $649.38k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. Thomas Michael Ross (Age 62)
    Executive Vice President of Global Sales & Marketing
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Dr. J. Stark Thompson Ph.D. (Age 81)
    Consultant
    Comp: $84.71k
  • Dr. James Brady Ph.D.
    Senior VP of Technical Applications & Customer Support














MXCT Stock Analysis - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings
or view top-rated stocks.

What is MaxCyte's stock price target for 2024?

3 brokerages have issued 12 month price objectives for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts price targets for MXCT
or view top-rated stocks among Wall Street analysts.

How have MXCT shares performed in 2023?

MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 13.0% and is now trading at $4.75.
View the best growth stocks for 2023 here
.

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our MXCT earnings forecast
.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $8.01 million for the quarter, compared to the consensus estimate of $7.90 million. MaxCyte had a negative net margin of 98.44% and a negative trailing twelve-month return on equity of 15.35%.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte issued an update on its third quarter 2023 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.80 million-$8.00 million, compared to the consensus revenue estimate of $11.35 million.

When did MaxCyte IPO?

(MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.89%), American Century Companies Inc. (1.65%), River & Mercantile Asset Management LLP (1.42%), Ameriprise Financial Inc. (1.26%) and Northern Trust Corp (0.77%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends
.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MXCT) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -